OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 527-540
Closed Access | Times Cited: 262
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 527-540
Closed Access | Times Cited: 262
Showing 1-25 of 262 citing articles:
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
Karin E. de Visser, Johanna A. Joyce
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 374-403
Open Access | Times Cited: 1595
Karin E. de Visser, Johanna A. Joyce
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 374-403
Open Access | Times Cited: 1595
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1193
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1193
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Zhenling Liu, Huanhuan Chen, Lili Zheng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 517
Zhenling Liu, Huanhuan Chen, Lili Zheng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 517
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Stephen L. Chan, Shanzhi Gu, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1133-1146
Closed Access | Times Cited: 370
Shukui Qin, Stephen L. Chan, Shanzhi Gu, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1133-1146
Closed Access | Times Cited: 370
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Pathological angiogenesis: mechanisms and therapeutic strategies
Andrew C. Dudley, Arjan W. Griffioen
Angiogenesis (2023) Vol. 26, Iss. 3, pp. 313-347
Open Access | Times Cited: 227
Andrew C. Dudley, Arjan W. Griffioen
Angiogenesis (2023) Vol. 26, Iss. 3, pp. 313-347
Open Access | Times Cited: 227
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Seyedehdelaram Ghalehbandi, Jale Yüzügülen, Md Zahidul Islam Pranjol, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175586-175586
Open Access | Times Cited: 140
Seyedehdelaram Ghalehbandi, Jale Yüzügülen, Md Zahidul Islam Pranjol, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175586-175586
Open Access | Times Cited: 140
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen Chen, Zehua Wang, Yi Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 135
Chen Chen, Zehua Wang, Yi Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 135
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 124
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 124
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment
Chenxi Ma, Chengzhe Yang, Ai Peng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 101
Chenxi Ma, Chengzhe Yang, Ai Peng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 101
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 98
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 98
WNT signaling and cancer stemness
Masuko Katoh, Masaru Katoh
Essays in Biochemistry (2022) Vol. 66, Iss. 4, pp. 319-331
Open Access | Times Cited: 95
Masuko Katoh, Masaru Katoh
Essays in Biochemistry (2022) Vol. 66, Iss. 4, pp. 319-331
Open Access | Times Cited: 95
Understanding tumour endothelial cell heterogeneity and function from single-cell omics
Qun Zeng, Mira Mousa, Aisha Shigna Nadukkandy, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 544-564
Closed Access | Times Cited: 93
Qun Zeng, Mira Mousa, Aisha Shigna Nadukkandy, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 544-564
Closed Access | Times Cited: 93
Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications
Jian-Wen Fang, Yue Lu, Jingyan Zheng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 9
Open Access | Times Cited: 87
Jian-Wen Fang, Yue Lu, Jingyan Zheng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 9
Open Access | Times Cited: 87
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Jason M. Schenkel, Kristen E. Pauken
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 807-823
Open Access | Times Cited: 66
Jason M. Schenkel, Kristen E. Pauken
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 807-823
Open Access | Times Cited: 66
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ehsan Ghorani, Charles Swanton, Sergio A. Quezada
Immunity (2023) Vol. 56, Iss. 10, pp. 2270-2295
Open Access | Times Cited: 50
Ehsan Ghorani, Charles Swanton, Sergio A. Quezada
Immunity (2023) Vol. 56, Iss. 10, pp. 2270-2295
Open Access | Times Cited: 50
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Amelie Franken, Michel Bila, Aurelie Mechels, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 541-558.e7
Open Access | Times Cited: 34
Amelie Franken, Michel Bila, Aurelie Mechels, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 541-558.e7
Open Access | Times Cited: 34
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 33
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 33
Tumour vasculature at single-cell resolution
Pan Xu, Xin Li, Liang Dong, et al.
Nature (2024) Vol. 632, Iss. 8024, pp. 429-436
Closed Access | Times Cited: 27
Pan Xu, Xin Li, Liang Dong, et al.
Nature (2024) Vol. 632, Iss. 8024, pp. 429-436
Closed Access | Times Cited: 27
Targeting the tumour vasculature: from vessel destruction to promotion
Sophie Guelfi, Kairbaan Hodivala‐Dilke, Gabriele Bergers
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 655-675
Closed Access | Times Cited: 27
Sophie Guelfi, Kairbaan Hodivala‐Dilke, Gabriele Bergers
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 655-675
Closed Access | Times Cited: 27
Endothelial cells in tumor microenvironment: insights and perspectives
Patrizia Leone, Eleonora Malerba, Nicola Susca, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
Patrizia Leone, Eleonora Malerba, Nicola Susca, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
Milestones in tumor vascularization and its therapeutic targeting
Michele De Palma, Douglas Hanahan
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 827-843
Closed Access | Times Cited: 17
Michele De Palma, Douglas Hanahan
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 827-843
Closed Access | Times Cited: 17
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 8
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 8
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 7
